Current treatment of Crimean–Congo hemorrhagic fever in children

References

• Mardani M, Keshtkar-Jahromi M. Crimean–Congo hemorrhagic fever. Arch. Iran Med.10(2), 204–214 (2007).
   PubMed Web of Science ®Google Scholar
• Chinikar S, Ghiasi SM, Hewson R, Moradi M, Haeri A. Crimean–Congo hemorrhagic fever in Iran and neighboring countries. J. Clin. Virol.47(2), 110–114 (2010).
   PubMed Web of Science ®Google Scholar
• Maltezou HC, Andonova L, Andraghetti R et al. Crimean–Congo hemorrhagic fever in Europe: current situation calls for preparedness. Euro. Surveill.15(10), 19504 (2010).
   PubMedGoogle Scholar
• Sheikh AS, Sheikh AA, Sheikh NS et al. Bi-annual surge of Crimean–Congo haemorrhagic fever (CCHF): a five-year experience. Int. J. Infect. Dis.9(1), 37–42 (2005).
   PubMed Web of Science ®Google Scholar
• Nabeth P, Cheikh DO, Lo B et al. Crimean–Congo hemorrhagic fever, Mauritania. Emerg. Infect. Dis.10(12), 2143–2149 (2004).
   PubMed Web of Science ®Google Scholar
• Tall A, Sall AA, Faye O et al. Two cases of Crimean–Congo haemorrhagic fever (CCHF) in two tourists in Senegal in 2004. Bull. Soc. Pathol. Exot.102(3), 159–161 (2009).
   PubMedGoogle Scholar
• Mardani M, Rahnavardi M, Rajaeinejad M et al. Crimean–Congo hemorrhagic fever among health care workers in Iran: a seroprevalence study in two endemic regions. Am. J. Trop. Med. Hyg.76(3), 443–445 (2007).
   PubMed Web of Science ®Google Scholar
• Izadi S, Salehi M, Holakouie-Naieni K, Chinikar S. The risk of transmission of Crimean–Congo hemorrhagic fever virus from human cases to first-degree relatives. Jpn J. Infect. Dis.61(6), 494–496 (2008).
   PubMed Web of Science ®Google Scholar
• Saijo M, Tang Q, Shimayi B et al. Possible horizontal transmission of Crimean–Congo hemorrhagic fever virus from a mother to her child. Jpn J. Infect. Dis.57(2), 55–57 (2004).
   PubMed Web of Science ®Google Scholar
• Izadi S, Naieni KH, Madjdzadeh SR, Nadim A. Crimean–Congo hemorrhagic fever in Sistan and Baluchestan Province of Iran, a case–control study on epidemiological characteristics. Int. J. Infect. Dis.8(5), 299–306 (2004).
   PubMed Web of Science ®Google Scholar
• Ozkurt Z, Kiki I, Erol S et al. Crimean–Congo hemorrhagic fever in Eastern Turkey: clinical features, risk factors and efficacy of ribavirin therapy. J. Infect.52(3), 207–215 (2006).
   PubMed Web of Science ®Google Scholar
• Swanepoel R, Shepherd AJ, Leman PA, Shepherd SP, Miller GB. A common-source outbreak of Crimean–Congo haemorrhagic fever on a dairy farm. S. Afr. Med. J.68(9), 635–637 (1985).
   PubMed Web of Science ®Google Scholar
• Hoogstraal H. The epidemiology of tick-borne Crimean–Congo hemorrhagic fever in Asia, Europe, and Africa. J. Med. Entomol.15(4), 307–417 (1979).
   PubMed Web of Science ®Google Scholar
• van Eeden PJ, van Eeden SF, Joubert JR, King JB, van de Wal BW, Michell WL. A nosocomial outbreak of Crimean–Congo haemorrhagic fever at Tygerberg Hospital. Part II. Management of patients. S. Afr. Med. J.68(10), 718–721 (1985).
   PubMed Web of Science ®Google Scholar
• Altaf A, Luby S, Ahmed AJ et al. Outbreak of Crimean–Congo haemorrhagic fever in Quetta, Pakistan: contact tracing and risk assessment. Trop. Med. Int. Health3(11), 878–882 (1998).
   PubMed Web of Science ®Google Scholar
• Smego RA Jr, Sarwari AR, Siddiqui AR. Crimean–Congo hemorrhagic fever: prevention and control limitations in a resource-poor country. Clin. Infect. Dis.38(12), 1731–1735 (2004).
   PubMed Web of Science ®Google Scholar
• Maltezou HC, Maltezos E, Papa A. Contact tracing and serosurvey among healthcare workers exposed to Crimean–Congo haemorrhagic fever in Greece. Scand. J. Infect. Dis.41(11–12), 877–880 (2009).
   PubMed Web of Science ®Google Scholar
• Dilber E, Cakir M, Acar EA et al. Crimean–Congo haemorrhagic fever among children in north-eastern Turkey. Ann. Trop. Paediatr.29(1), 23–28 (2009).
   PubMed Web of Science ®Google Scholar
• Sharifi-Mood B, Mardani M, Keshtkar-Jahromi M, Rahnavardi M, Hatami H, Metanat M. Clinical and epidemiologic features of Crimean–Congo hemorrhagic fever among children and adolescents from southeastern Iran. Pediatr. Infect. Dis. J.27(6), 561–563 (2008).
   PubMed Web of Science ®Google Scholar
• Tezer H, Sayli TR, Metin A, Koker Y, Devrim I, Ergonul O. Lymphocyte subgroups in children with CCHF: a marker for prognosis. J. Infect.59(4), 291–293 (2009).
   PubMed Web of Science ®Google Scholar
• Tanir G, Tuygun N, Balaban I, Doksoz O. A case of Crimean–Congo hemorrhagic fever with pleural effusion. Jpn J. Infect. Dis.62(1), 70–72 (2009).
   PubMed Web of Science ®Google Scholar
• Ahmeti S, Raka L. Crimean–Congo haemorrhagic fever in Kosova: a fatal case report. Virol. J.3, 85 (2006).
   PubMedGoogle Scholar
• Whitehouse CA. Crimean–Congo hemorrhagic fever. Antiviral Res.64(3), 145–160 (2004).
   PubMed Web of Science ®Google Scholar
• Swanepoel R, Shepherd AJ, Leman PA et al. Epidemiologic and clinical features of Crimean–Congo hemorrhagic fever in southern Africa. Am. J. Trop. Med. Hyg.36(1), 120–132 (1987).
   PubMed Web of Science ®Google Scholar
• Sharifi-Mood B, Metanat M, Ghorbani-Vaghei A, Fayyaz-Jahani F, Akrami E. The outcome of patients with Crimean–Congo hemorrhagic fever in Zahedan, southeast of Iran: a comparative study. Arch. Iran. Med.12(2), 151–153 (2009).
   PubMed Web of Science ®Google Scholar
• Ergönül O, Celikbas A, Dokuzoguz B, Eren S, Baykam N, Esener H. Characteristics of patients with Crimean–Congo hemorrhagic fever in a recent outbreak in Turkey and impact of oral ribavirin therapy. Clin. Infect. Dis.39(2), 284–287 (2004).
   PubMed Web of Science ®Google Scholar
• Schwarz TF, Nsanze H, Ameen AM. Clinical features of Crimean–Congo haemorrhagic fever in the United Arab Emirates. Infection25(6), 364–367 (1997).
   PubMed Web of Science ®Google Scholar
• Vorou R, Pierroutsakos IN, Maltezou HC. Crimean–Congo hemorrhagic fever. Curr. Opin. Infect. Dis.20(5), 495–500 (2007).
   PubMed Web of Science ®Google Scholar
• Swanepoel R, Gill DE, Shepherd AJ, Leman PA, Mynhardt JH, Harvey S. The clinical pathology of Crimean–Congo hemorrhagic fever. Rev. Infect. Dis.11(Suppl. 4), S794–S800 (1989).
   PubMedGoogle Scholar
• Ergonul O. Treatment of Crimean–Congo hemorrhagic fever. Antiviral Res.78(1), 125–131 (2008).
   PubMed Web of Science ®Google Scholar
• Izadi S, Salehi M. Evaluation of the efficacy of ribavirin therapy on survival of Crimean–Congo hemorrhagic fever patients: a case–control study. Jpn J. Infect. Dis.62(1), 11–15 (2009).
   PubMed Web of Science ®Google Scholar
• Tasdelen Fisgin N, Ergonul O, Doganci L, Tulek N. The role of ribavirin in the therapy of Crimean–Congo hemorrhagic fever: early use is promising. Eur. J. Clin. Microbiol. Infect. Dis.28(8), 929–933 (2009).
   PubMed Web of Science ®Google Scholar
• Ergonul O. Crimean–Congo haemorrhagic fever. Lancet Infect. Dis.6(4), 203–214 (2006).
   PubMed Web of Science ®Google Scholar
• Levi M, Opal SM. Coagulation abnormalities in critically ill patients. Crit. Care10(4), 222 (2006).
   PubMed Web of Science ®Google Scholar
• Taylor FB Jr, Toh CH, Hoots WK, Wada H, Levi M. Towards definition, clinical and laboratory criteria, and a scoring system for disseminated intravascular coagulation. Thromb. Haemost.86(5), 1327–1330 (2001).
   PubMed Web of Science ®Google Scholar
• Stanworth SJ. The evidence-based use of FFP and cryoprecipitate for abnormalities of coagulation tests and clinical coagulopathy. Hematology Am. Soc. Hematol. Educ. Program179–186 (2007).
   PubMedGoogle Scholar
• Mannucci PM. Desmopressin (DDAVP) in the treatment of bleeding disorders: the first 20 years. Blood90(7), 2515–2521 (1997).
   PubMed Web of Science ®Google Scholar
• Levi M, Cromheecke ME, de Jonge E et al. Pharmacological strategies to decrease excessive blood loss in cardiac surgery: a meta-analysis of clinically relevant endpoints. Lancet354(9194), 1940–1947 (1999).
   PubMed Web of Science ®Google Scholar
• Graci JD, Cameron CE. Mechanisms of action of ribavirin against distinct viruses. Rev. Med. Virol.16(1), 37–48 (2006).
   PubMed Web of Science ®Google Scholar
• Watts DM, Ussery MA, Nash D, Peters CJ. Inhibition of Crimean–Congo hemorrhagic fever viral infectivity yields in vitro by ribavirin. Am. J. Trop. Med. Hyg.41(5), 581–585 (1989).
   PubMed Web of Science ®Google Scholar
• Tignor GH, Hanham CA. Ribavirin efficacy in an in vivo model of Crimean–Congo hemorrhagic fever virus (CCHF) infection. Antiviral Res.22(4), 309–325 (1993).
   PubMed Web of Science ®Google Scholar
• Paragas J, Whitehouse CA, Endy TP, Bray M. A simple assay for determining antiviral activity against Crimean–Congo hemorrhagic fever virus. Antiviral Res.62(1), 21–25 (2004).
   PubMed Web of Science ®Google Scholar
• Fisher-Hoch SP, Khan JA, Rehman S, Mirza S, Khurshid M, McCormick JB. Crimean Congo-haemorrhagic fever treated with oral ribavirin. Lancet346(8973), 472–475 (1995).
   PubMed Web of Science ®Google Scholar
• Mardani M, Jahromi MK, Naieni KH, Zeinali M. The efficacy of oral ribavirin in the treatment of Crimean–Congo hemorrhagic fever in Iran. Clin. Infect. Dis.36(12), 1613–1618 (2003).
   PubMed Web of Science ®Google Scholar
• Metanat M S-MB, Salehi M, Alavi-Naini R. Clinical outcome in Crimean–Congo hemorrhagic fever: a five-year experience in the treatment of patients in oral ribavirin. Int. J. Virol.2, 21–24 (2006).
   Google Scholar
• Vassilenko SM, Vassilev TL, Bozadjiev LG, Bineva IL, Kazarov GZ. Specific intravenous immunoglobulin for Crimean–Congo haemorrhagic fever. Lancet335(8692), 791–792 (1990).
   PubMed Web of Science ®Google Scholar
• Andersson I, Bladh L, Mousavi-Jazi M et al. Human MxA protein inhibits the replication of Crimean–Congo hemorrhagic fever virus. J. Virol.78(8), 4323–4329 (2004).
   PubMed Web of Science ®Google Scholar
• Rahnavardi M, Rajaeinejad M, Pourmalek F, Mardani M, Holakouie-Naieni K, Dowlatshahi S. Knowledge and attitude toward Crimean–Congo haemorrhagic fever in occupationally at-risk Iranian healthcare workers. J. Hosp. Infect.69(1), 77–85 (2008).
   PubMed Web of Science ®Google Scholar
• van de Wal BW, Joubert JR, van Eeden PJ, King JB. A nosocomial outbreak of Crimean–Congo haemorrhagic fever at Tygerberg Hospital. Part IV. Preventive and prophylactic measures. S. Afr. Med. J.68(10), 729–732 (1985).
   PubMed Web of Science ®Google Scholar
• Tang Q, Saijo M, Zhang Y et al. A patient with Crimean–Congo hemorrhagic fever serologically diagnosed by recombinant nucleoprotein-based antibody detection systems. Clin. Diagn. Lab. Immunol.10(3), 489–491 (2003).
   PubMedGoogle Scholar
• Cevik MA, Elaldi N, Akinci E et al. A preliminary study to evaluate the effect of intravenous ribavirin treatment on survival rates in Crimean–Congo hemorrhagic fever. J. Infect.57(4), 350–351 (2008).
   PubMed Web of Science ®Google Scholar
• Buckingham SC. Tick-borne infections in children: epidemiology, clinical manifestations, and optimal management strategies. Paediatr. Drugs7(3), 163–176 (2005).
   PubMedGoogle Scholar
• Tatar A, Ozkurt Z, Kiki I. Genotoxic effect of ribavirin in patients with Crimean–Congo hemorrhagic fever. Jpn J. Infect. Dis.58(5), 313–315 (2005).
   PubMed Web of Science ®Google Scholar
• Long CE, Voter KZ, Barker WH, Hall CB. Long term follow-up of children hospitalized with respiratory syncytial virus lower respiratory tract infection and randomly treated with ribavirin or placebo. Pediatr. Infect. Dis. J.16(11), 1023–1028 (1997).
   PubMed Web of Science ®Google Scholar
• Andersson I, Karlberg H, Mousavi-Jazi M, Martinez-Sobrido L, Weber F, Mirazimi A. Crimean–Congo hemorrhagic fever virus delays activation of the innate immune response. J. Med. Virol.80(8), 1397–1404 (2008).
   PubMed Web of Science ®Google Scholar